Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
We combine clinical and experimental data through machine learning techniques to explore human disease biology and promote the development of precision medicine. Our innovative Contingent AI™ technology comprehends the intricate relationships present in the data, yielding advanced insights. To combat data bias, we refine our machine learning models based on decisions made during the pre-processing and feature engineering phases. We utilize zebrafish, cellular, and various phenotypic animal models to test and confirm in silico predictions through in vivo experiments, along with genetic modifications conducted both in vitro and in vivo to enhance translation. By employing active learning and computer vision on validated models that focus on cardiac, central nervous system, and rare disorders, we swiftly integrate new data into our machine learning frameworks, allowing for continuous improvement and adaptation in our methodologies. This iterative process not only enhances the accuracy of our predictions but also enables us to stay at the forefront of research in precision medicine.
Description
Behavioral health constitutes a crucial yet frequently neglected component of overall wellness. The impact of mental and substance use disorders affects an astonishing 970 million individuals globally, contributing to an economic burden exceeding US $1 trillion each year. In spite of this escalating crisis, advancements in treatment and understanding have not kept pace with other medical fields. Alarmingly, less than half of those suffering from major depression, which is the most prevalent mental health disorder, achieve remission with existing therapies. Increased awareness has sparked a greater demand for services in a system that remains ill-equipped to address the extensive complexities of this need. There exists a significant evidence gap that hinders progress in research and innovation, largely due to the inherent challenges within behavioral health, such as intricate disease causes, a shortage of measurable biomarkers, and fragmented institutional approaches. Even after many years of dedicated research, we remain largely in the dark about how to effectively treat most behavioral health conditions, indicating a critical need for renewed focus and resources in this field. Ultimately, bridging this gap is essential for improving the lives of millions affected by these disorders.
API Access
Has API
API Access
Has API
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
BioSymetrics
Country
United States
Website
www.biosymetrics.com/platform
Vendor Details
Company Name
Holmusk
Founded
2015
Country
Singapore
Website
www.neuroblu.ai/